1. Introduction {#s0005}
===============

Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease (MND) characterised by lower motor neuron (LMN) degeneration ([@bb0065]) due to loss of function of the survival-motor-neuron 1 (SMN1) gene ([@bb0080]). SMA exhibits considerable clinical heterogeneity with four main phenotypes being distinguished based on age of onset and reaching of developmental milestones ([@bb0165]). A key determinant of the clinical presentation is the SMN2 copy number, which is a more centromeric and only partially functional copy of SMN1. Higher SMN2 copy numbers are thought to inversely correlate with disease severity ([@bb0060]).

SMA type III is considered a relatively milder form of the disease with preserved acquisition of ambulation and is traditionally subdivided into SMA IIIa, with onset before 3 years of age, and SMA IIIb (onset after the age of 3) ([@bb0120]). SMA type IV refers to adult onset ([@bb0165]; [@bb0120]). Both forms have relatively slow ([@bb0010]), non-linear ([@bb0165]; [@bb0040]) progression rates with tendency to plateau over time and usually present with proximal and symmetrical muscle weakness ([@bb0065]; [@bb0165]). The pathophysiological mechanisms behind this distinct clinical phenotype are poorly understood, especially considering that SMN is a ubiquitously expressed protein ([@bb0180]). Several explanations have been proposed for the strikingly localised effect of this protein deficiency, including the selective vulnerability of motor neuron pools (MN) in the spinal cord (SC) ([@bb0125]; [@bb0030]). Despite these observations, post mortem studies of infantile SMA suggest that neuropathological involvement extends well beyond MN degeneration in the anterior horns, and affect the posterior columns and cerebral regions such as the thalamus ([@bb0150]; [@bb0090]). Central nervous system (CNS) involvement has also been demonstrated in mouse models of SMA, with reduction of hippocampal volumes and motor cortex degeneration ([@bb0175]). Nevertheless, CNS involvement has not been comprehensively studied in adult SMA patients to date and motor cortex and cortico-spinal tract (CST) degeneration have never been specifically evaluated. In recent years, SC imaging has seen unprecedented advances and has been successfully used in MNDs to characterise grey ([@bb0115]) and white ([@bb0135]) matter pathology in cross-sectional, longitudinal ([@bb0020]) and prognostic studies ([@bb0130]; [@bb0050]). Despite the momentous technical advances in spinal imaging, only one SMA study confirmed SC atrophy using quantitative MRI ([@bb0055]).

The objective of this study is the comprehensive characterisation of spinal and cerebral pathology using state-of-the-art quantitative imaging tools in a cohort of type III and type IV SMA patients. Our main hypothesis is that advanced spinal imaging techniques can detect and characterise GM pathology. A secondary hypothesis is that limited WM pathology will be captured. Finally, based on evidence from animal studies and other MNDs, cerebral pathology is also suspected.

2. Methods {#s0010}
==========

2.1. Study population {#s0015}
---------------------

Twenty-five genetically confirmed type III (*n* = 19) and type IV (*n* = 6) SMA patients and 25 gender- and age-matched healthy controls (HCs) were recruited in a prospective multimodal spinal and cerebral neuroimaging study (NCT0288587). The study protocol was approved by the Ethics Committee of the Pitié-Salpêtrière University Hospital (Paris) and all the participants provided informed consent. All the procedures included in the protocol were conducted in accordance with the Helsinki declaration.

The patients underwent genetic testing, confirming the diagnosis of SMN1-related SMA. Based on current consensus criteria ([@bb0100]), patients were diagnosed as SMA type III if symptom onset was after 18-month of age and if they learnt to walk on time. Patients with onset before 3 years were diagnosed with SMA type IIIa, while patients with onset between 3 and 18 years of age were diagnosed with SMA type IIIb. Patients with symptom onset after 18 years of age where considered as having SMA type IV ([@bb0170]).

Exclusion criteria included prior CNS pathology and presence of medical devices incompatible with high-field MR imaging.

2.2. Neuromuscular evaluation {#s0020}
-----------------------------

All participants underwent standardized neurological assessment including muscle strength evaluation through the Medical Research Council (MRC) scores in the deltoid, biceps brachii, triceps brachii, extensor carpi, opponens pollicis and flexor digitorum profundus muscles for upper limbs (UL) and in the iliopsoas, hip abductors, quadriceps femoris, hamstrings, anterior tibialis, gastrocnemius, and extensor hallucis longus muscles for lower limbs (LL). All muscles were tested bilaterally and cumulative scores for UL and LL were computed.

The Motor Function Measure (MFM) scale was used as standardized score for the evaluation of global motor impairment ([@bb0160]; [@bb0105]). The MFM scale is composed of 32 items grouped in 3 functional domains: standing and transfers (D1 sub-score), axial and proximal motor function (D2 sub-score), and distal motor function (D3 sub-score). Cumulative scores are typically expressed as the percentage of the maximum possible score.

2.3. Cervical spinal cord (SC) acquisition protocol {#s0025}
---------------------------------------------------

SMA patients and HCs underwent a 3 T cervical SC MR imaging (MAGNETOM Prisma, Siemens Healthcare, Erlangen, Germany, 64-channel head and neck coil). Anatomical imaging between C2 and C7 spinal levels included a sagittal 3D T2-weighted fast spin-echo SPACE sequence and an axial 2D T2\*-weighted multi-echo gradient echo sequence (MEDIC) providing high GM-WM contrast ([@bb0095]). The main imaging parameters for the T2-weighted sequences were: slab selective excitation, voxel size = 0.8 × 0.8 × 0.8 mm^3^, FOV = 256 × 256 mm^2^, 72 sagittal slices, TR/TE = 1500/131 ms, acceleration factor *R* = 2. T2\*-weighted imaging parameters were: voxel size = 0.5 × 0.5 × 5 mm^3^, FOV = 180 × 180 mm^2^, TR/ TE = 470/17 ms, flip angle = 30°, seven slabs. T2\*-weighted images were acquired at the middle of each cervical vertebral level and perpendicular to the SC axis.

Spine diffusion tensor imaging (DTI) data were acquired using a reduced field of view EPI sequence with high angular resolution (HARDI) with two axial slabs containing three slices each (C2 to C4 and C5 to C7 vertebral levels). Imaging parameters were: b = 1000 s/mm^2^, 60 diffusion-encoding gradient directions, voxel size = 8 × 0.8 × 5 mm^3^, FOV = 45 × 128 mm^2^, TR/TE = 500/73 ms, cardiac gating.

2.4. Spinal cord MRI data processing {#s0030}
------------------------------------

Data processing was performed using the Spinal Cord Toolbox v3.1 (SCT) ([@bb0025]). Raw data were first reviewed for acquisition quality and incidental findings. T2-weighted and multimodal MR images were automatically registered to a common template image. Total CSA was extracted at each vertebral level from the T2-weighted images and expressed in mm^2^.

GM and WM were automatically segmented on the T2\*-weighted image and WM-CSA and GM-CSA were calculated in mm^2^ ([@bb0025]) ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Segmentation and vertebral labelling of cervical spinal cord MRI images.Automated spinal cord segmentation and vertebral labelling on sagittal (a) and axial (b) T2-weighted images resulting in cross-sectional area estimations (mm^2^). c: sample T2\*-weighted images with high GM/WM contrast enabling grey-white matter segmentation and cross-sectional area calculation (mm^2^).Fig. 1

DTI images were co-registered in the PAM50 template-space ([@bb0025]). Motion and Eddy-current corrections were first performed and subsequently the four main diffusivity metrics were computed: fractional anisotropy (FA), radial diffusivity (RD), axial diffusivity (AD) and mean diffusivity (MD). Using template-based analyses, DTI parameters were calculated for the medial and lateral CSTs and for the dorsal columns.

3. Brain MRI acquisition protocol {#s0035}
=================================

Cerebral MR data were acquired using a 64-channel head coil. DTI acquisition parameters were: TE = 73 ms, TR = 3490 ms, dimensions: 116x116x84 and an isometric voxel size of 1.81 × 1.81 × 1.81 mm. 3D T1-weighted imaging data were acquired with TE = 2.22 ms, TR = 2400 ms, dimension matrix: 300x320x256 and an isometric voxel size of 1x1x1 mm. Brain MRI data were pre-processed for 25 SMA patients and 25 HC. After quality verification procedures, brain MRI data was discarded for one SMA patient and two HCs due to movement artefacts.

4. Brain MRI data processing {#s0040}
============================

4.1. Cortical thickness analyses {#s0045}
--------------------------------

The FreeSurfer image analysis suite was used to carry out cortical thickness measurements and comparative statistics ([@bb0070]). Standard pre-processing steps were implemented, including motion correction, averaging of the structural T1-weighted data, removal of non-brain tissue, segmentation of the subcortical WM and deep GM structures, intensity normalization, tessellation of the GM-WM boundary, and automated topology correction. False Discovery Rate (FDR) correction was used to correct for multiple comparisons at *p* \< .05 and group comparisons were corrected for gender and age.

4.2. Grey matter analyses {#s0050}
-------------------------

GM morphometry analyses were carried out using standard pipelines as implemented in FMRIB\'s software library (FSL) ([@bb0140]). Following brain extraction, motion-correction and tissue-type segmentation, GM partial volume images were aligned to MNI152 standard space using non-linear registration. An equal number (23−23) of SMA and control images were used to generate a symmetric, study-specific grey matter template. All native GM images were then non-linearly registered to this study-specific template, modulated by a Jacobian field warp and smoothed with an isotropic Gaussian kernel with a sigma of 3 mm. The threshold-free cluster enhancement (TFCE) method and permutation-based nonparametric inference was used for the comparisons of the SMA patients and HCs accounting for age and gender. Statistical significance was set at *p* \< .05 FWE.

4.3. White matter analyses {#s0055}
--------------------------

Raw DTI datasets underwent Eddy current corrections, motion correction and brain-tissue extraction using FSL ([@bb0145]). A diffusion tensor model was then fitted, generating maps of AD, RD, MD and FA. Tract-based spatial statistics (TBSS) ([@bb0145]) and permutation-based nonparametric inference was used for group comparisons in a study-specific WM template applying the TFCE method. Design matrices included age and gender as covariates, and statistical significance was set at p \< .05 FWE.

4.4. Region of interest (ROI) analyses {#s0060}
--------------------------------------

In addition to standard 'whole-brain' morphometry and TBSS, we performed ROI GM and WM analyses in the motor cortex and CSTs to specifically explore UMN associated degeneration. All ROI analyses were performed in the study-specific template space on our 4D data sets. The left and right hemispheric portion of the precentral gyrus label of the Harvard-Oxford cortical probability atlas were used to generate the motor cortex ROI mask (supplementary fig. 1). The Harvard-Oxford probabilistic atlas includes labels for 48 cortical and 21 subcortical structural areas ([@bb0035]). Two types of ROI analyses were performed. First, permutation-based, design-matrix defined non-parametric statistics were preformed in our motor cortex mask using FSL, thresholded and visualised just as in our standard, 'whole-brain' morphometry analyses. In a supplementary analysis, average GM probability values were retrieved from the above cortical masks to perform additional post hoc analyses. Comparative statistics of ROI-GM-data were explored using ROI-GM probability as dependent variable, study group affiliation as the categorical independent variable and age and gender as covariates.

WM-ROIs were defined by masking the study-specific WM skeleton by the left and right CST labels of the Jülich histological atlas in MNI space ([@bb0045]). (supplementary fig. 1) First a TBSS-type analysis was performed in the above CST mask for the four main diffusion metrics. Subsequently, average AD, RD, MD and FA values were retrieved from the left and right CST masks from the skeletonised 4D WM data and fed into post hoc statistics. Age and gender were used as covariates when comparing diffusivity values between SMA patients and controls.

5. Statistical analyses {#s0065}
=======================

Statistical analyses were performed using JMP 13 Pro. Shapiro-Wilk test was applied to test for normality. Descriptive variables such as mean, median, standard deviation, percentage and range were used to summarise quantitative measures. Group comparisons of normally distributed variables were performed using *t*-tests. For non-normally distributed data, the 2-tailed unpaired Mann-Whitney *U* test was used. The Chi-squared test was used to compare categorical data.

Spearman\'s correlation coefficient was used to assess correlations and FDR was used to correct for multiple correlations. The significance level was set at *p* \< .05.

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

6. Results {#s0070}
==========

6.1. Clinical and neuromuscular evaluation {#s0075}
------------------------------------------

The demographic and neuromuscular profile of participants is summarized in [Table 1](#t0005){ref-type="table"}.Table 1Demographic, clinical and functional parameters of study participants described as mean value and standard deviation. MFM = muscle function measure. Cumulative mega-scores for proximal and distal muscle strength were calculated as follows: [UL proximal score]{.ul}: deltoid, biceps brachii, triceps brachii; [UL distal score:]{.ul} extensor carpi, opponens pollicis, flexor digitorum profundus; [LL proximal score:]{.ul} iliopsoas, hip abductors, quadriceps femoris, hamstrings; [LL distal score:]{.ul} anterior tibialis, gastrocnemius, extensor hallucis longus for lower limbs.Table 1SMA patientsHealthy controls*p*-valueAge41.38 +/− 13.25 (range 18--66)37.00 +/− 10.31 (range 18--57)*p* = .219Sex13 M:12F12 M:13F*p* = .778Handedness21 Right-handed: 4 Left-handed23 Right-handed: 2 Left-handed*p* = .140Age at symptoms\' onset (years)11.00 +/− 7.01 (range 1--22)N/aAge at molecular diagnosis (years)18.32 +/− 13.20 (range 1--58)N/aAge at walking acquisition (months)14.16 +/− 3.82 (range 12--24)N/aDisease duration at evaluation (years)30.38 +/− 15.40 (range 5--55)N/aUpper limbs force mega score (max 70)57.72 +/− 13.52 (range 38--70)N/aUpper limbs proximal force megascore (max 30)23.60 +/− 7.02 (range 10--30)N/aUpper limbs distal force megascore (max 40)34.12 +/− 6.73 (range 24--40)N/aLower limbs force mega score (max 70)49.24 +/− 15.51 (range 15--70)N/aLower limbs proximal force megascore (max 40)21.96 +/− 11.09 (range 0--40)N/aLower limbs distal force megascore (max 30)27.28 +/− 5.28 (range 12--30)N/aMFM total score %60.51 +/− 33.56 (range 0--100)N/aMFM D1 score %38.44 +/− 33.50 (range 0--100)N/aMFM D2 score %70.99 +/− 40.67 (range 0--100)N/aMFM D3 score %79.59 +/− 39.67 (range 0--100)N/a

None of the patients had significant comorbidities and patients were not on disease-modifying therapies. Based on consensus criteria ([@bb0100]; [@bb0170]), 5 patients were classified as SMA type IIIa, 14 as SMA IIIb and 6 as SMA type IV (supplementary table 1). SMN2 copy number was only available for 12 out of 25 patients: all of them had 4 copies of the gene except 2 type IIIb SMA, who had 3 copies (age at symptom onset 12 and 15 years respectively). No correlation was found between SMN2 copy number and age of symptom onset, neuromuscular parameters or disease duration.

None of the patients had evidence of bulbar involvement. 18 patients (72%) were ambulant and 7 patients were non-ambulant (28%). Both muscle weakness and muscle wasting were strikingly symmetric (no significant difference was found in the muscle strength between the right and the left side for each tested muscle, *p* \> .05) and predominantly proximally both in the UL and LL. Proximal muscle involvement was also captured by D1 MFM sub-score reduction (61.6% of maximal score), representing the ability to maintain a standing position.

A significant association was identified between muscle strength and disease duration (supplementary table 2).

6.2. Spinal cord MRI analyses {#s0080}
-----------------------------

Significant CSA differences were identified between SMA patients and HCs at each vertebral level (all *p* \< .05, not FDR corrected) as shown in [Fig. 2](#f0010){ref-type="fig"}. More importantly, multilevel GM-CSA reductions were captured: at C2 (*p* \< .001, consistent with a 10.73% reduction compared to HCs), at C2-C3 (*p* = .001, 12.77% reduction), C3-C4 (p \< .001, 18.19% reduction), C4-C5 (*p* = .026, 11.29% reduction) and at C5-C6 (*p* = 0,006, 15.13% reduction). No GM-CSA reduction was identified at C6-C7 level compared to controls (*p* = .306) ([Fig. 3](#f0015){ref-type="fig"}). No significant WM-CSA reductions nor significant diffusivity differences were identified in SMA patients compared to controls, supporting the lack of WM degeneration in SMA (supplementary tables 3 and 4).Fig. 2The spinal cord atrophy profile of SMA patients.a: Total cross-sectional area values for each vertebral level presented as mean, standard deviation and comparative *p*-values between SMA patients and healthy controls. b: Grey matter cross-sectional area for each vertebral level presented as mean, standard deviation and comparative p-value between SMA patients and healthy controls c: Visual representation of grey matter atrophy profile of SMA patients expressed as mean CSA and relative standard deviation. CSA = cross-sectional area (mm2) Green colour indicates healthy controls and blue colour indicates the grey matter profile of SMA patients. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2Fig. 3Graphical representation of total CSA, GM and WM-CSA for each vertebral level.CSA is measured in mm^2^. Significant differences are indicated by asterisks. Green colour indicates healthy controls, red colour depicts the spinal cord profile of patients with SMA. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 3

Significant correlation was also observed between GM-CSA at C3-C4 level and deltoid muscle strength (*r* = 0.41, *p* = .05). No other correlation was found between SC MRI parameters and functional scores. To examine the possible effect of disease-duration and explore differences between type III and type IV SMA patients, additional post hoc tests were performed. No significant differences were identified between the two cohorts for any of the spinal parameters (p \> .05) and no correlation was detected between age or disease duration and spinal MRI metrics (total CSA or GM-CSA for C2-C7 vertebral levels).

6.3. Brain MRI analyses {#s0085}
-----------------------

Standard voxel-based morphometry (VBM) revealed multiple foci of increased GM density in SMA patients compared to HCs at *p* \< .05 FWE TFCE. These regions included the bilateral anterior cingulate, orbitofrontal cortices, aspects of the dorsolateral pre-frontal cortex and significant portions of the precentral gyrus representing the motor cortex ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4Increased grey matter density in SMA patients described by voxel-based-morphometry.(A) Increased grey matter density in SMA patients compared to healthy controls at *p* \< .05 FWE (TFCE, age and gender corrections) identified by VBM. MNI coordinates are provided for the relevant axial, sagittal and coronal views. (B) Region of interest (ROI) morphometry in the motor cortex (yellow) highlights a focus of increased grey matter density in SMA patients compared to controls at p \< .05 FWE TFCE. MNI coordinates of the focus (red) are indicated on the right bottom corner of the figure. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 4

Cortical thickness analyses and 'whole-brain' TBSS did not identify statistically significant differences between SMA patients and controls. Similarly, 'whole-brain' TBSS did not reveal WM alterations. Based on the increased GM density highlighted by VBM, supplementary ROI analyses were performed in the motor cortex and CSTs. Motor cortex ROI analyses highlighted a focus of increased GM density in SMA patients in the right precentral gyrus (p \< .05 FWE), which is anatomically consistent with the hand representation of the motor homunculus ([Fig. 4](#f0020){ref-type="fig"}, section B). Based on retrieved T1 data, SMA patients exhibited higher average density values in the right motor cortex (*p* = .047) and a trend was also observed in the left motor cortex (*p* = .066). CST-based TBSS analyses did not identify significant WM integrity differences between SMA patients and HCs. Similarly, comparisons of CST diffusivity metrics between SMA patients and controls did not reach statistical significance. The boxplots of raw GM and WM metrics are presented in [Fig. 5](#f0025){ref-type="fig"}. The means, standard deviation and comparison of raw ROI values are reported in supplementary table 5.Fig. 5Comparison of ROI-defined grey and white matter metrics between SMA patients and healthy controls. Boxplots represent raw data in controls (green) and SMA patients (orange). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 5

Increased cortical volume was observed in SMA type IV compared to type III patients in the left motor cortex (*p* = .0108), and a similar trend was also observed on the right (*p* = .08). A significant correlation was observed between disease duration and motor cortex volumes; Spearman\'s rho: −0.413 in the left with FDR corrected *p* = .022 and − 0.51 in the right side with FDR corrected *p* = .020. No association was identified between age at onset and cortical volumes; Spearman\'s rho = 0.32 in the left side and 0.29 in the right, corresponding FDR-corrected *p*-values = .12 and 0.10 respectively.

7. Discussion {#s0090}
=============

Our study confirms the presence of considerable multi-level cervical spinal cord atrophy in SMA ([@bb0050]). Spinal atrophy seems to be primarily driven by GM degeneration, that was most pronounced between the C3 and C5 vertebral levels, while no atrophy was identified at C6-C7, mirroring the proximal predominance of muscle weakness. Moreover, no WM atrophy was detected by CSA and DTI measurements. Despite sample size limitations, our findings suggest that mechanisms underlying MN degeneration in SMA are different from those taking place in other MNDs, such as ALS ([@bb0115]; [@bb0020]; [@bb0130]). The sparing of white matter was further supported by brain imaging, which detected no WM alterations in the CSTs despite using a dual whole-brain, and ROI approach. Interestingly, increased GM density was identified in the motor cortex of SMA patients compared to controls, which was further confirmed by ROI analyses. The presence of selective cortical hypertrophy in key motor regions needs careful interpretation, especially given the relatively small number of study participants. Notwithstanding these limitations, increased cortical volumes may be interpreted as an attempted compensatory mechanism in face of progressive LMN degeneration and discussed from a plasticity perspective. The reorganisation of motor regions is well recognised and has not only been reported in response to repetitive tasks ([@bb0015]), but also in patients with perinatal brain injuries, where increased GM density and cortical thickness is often identified in the contralateral hemisphere ([@bb0085]). The best known example of cortical hypertrophy in response to a repetitive cognitive task is the increased hippocampal volume of London taxi drivers famously described by Maguire et al. Such compensatory mechanisms however are known to be more evident in children and there may be a critical period for effective brain reorganisation to take place ([@bb0005]). Both type III and IV SMA patients start to develop LMN degeneration early in life and therefore may be more likely to exhibit effective cortical adaptation. Moreover, similar mechanisms have been previously proposed to explain superior language skills in SMA, which was also interpreted as a compensatory response ([@bb0155]). Our post-hoc grey matter analyses revealed increased motor cortex volumes in the type IV SMA cohort compared to type III patients and we identified a significant correlation between disease duration and cortical volumes. We acknowledge that these findings should be interpreted with caution because of the limited sample size of the two cohorts. Nevertheless, they suggest that increased cortical volumes may represent a compensatory mechanism or cortical reorganisation which is more evident in patients with slower progression rates and longer disease duration. This interpretation is merely a hypothesis until our findings are replicated by other groups and validated in larger SMA cohorts.

The specific cellular mechanisms underlying the observed cortical changes in our SMA cohort remain to be elucidated. Dendritic spine density has been recently linked to VBM measures ([@bb0075]) in a study of neural plasticity in mice, showing that increased VBM signal was associated with an increase in dendritic spine density. Based on our findings, we propose that adaptive compensatory mechanisms may take place in SMA which may be driven by dendrite density modifications. We acknowledge that these are merely hypotheses which need extensive validation by imaging studies in independent cohorts and ultimately by histopathological evaluation.

Our study is not without limitations. Larger cohort sizes and more robust stratification of type III and IV SMA patients may be desirable and a longitudinal study would be a natural extension of our proof-of-concept findings. We did not capture correlations between SMN2 copy numbers and clinical or neuroimaging measures, but we SMN2 copy numbers were not available for all participants. Moreover, even if WM involvement was not identified at a spinal or cerebral level, due to methodological constraints WM degeneration in SMA cannot be completely ruled out. We need to specifically acknowledge the limitation of region-of interest methods. While standard, 'whole-brain' analyses readily confirmed increased cortical volumes in the motor cortex, ([Fig. 4](#f0020){ref-type="fig"}) ROI type approaches are susceptible to spatial registration and modulation bias.

8. Conclusions {#s0095}
==============

Our spinal and cerebral findings suggest that adult forms of SMA are manifestations of selective anterior horn degeneration, which may begin long before symptom onset, allowing for attempted cortical compensation. Our finding of SMA-associated grey matter hypertrophy in the primary motor cortex needs to be replicated in large independent patient cohorts. While correlations between disease-duration and cortical volumes and differences between type III and type IV patients may support the notion of compensatory cerebral processes and cortical reorganisation, this interpretation needs to be carefully validated in large, prospective longitudinal studies. The relatively slow disease progression rates in type III and type IV SMA may allow for adaptive changes to take place. Interestingly, even after long disease duration, our cohort of SMA patients does not exhibit evidence of retrograde UMN degeneration. Mechanisms contributing to isolated LMN loss without UMN involvement are of particular interest given the paucity of slow-progressing animal models of SMA and the divergent reports from other LMN-dominant MNDs ([@bb0110]). The characterisation of SMA-associated spinal and cerebral pathology and the development of disease-specific biomarkers are particularly timely given the emergence of effective disease-modifying therapies and promising pharmacological trials in SMA.
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